{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/haematological-cancers-recognition-referral/management/referral-for-haematological-cancer/","result":{"pageContext":{"chapter":{"id":"cfe47d3f-300b-5be4-b4da-3dd966fef722","slug":"referral-for-haematological-cancer","fullItemName":"Scenario: Referral for haematological cancer","depth":2,"htmlHeader":"<!-- begin field 7d80a1fa-d725-4b72-a765-130660c4893f --><h2>Scenario: Referral for haematological cancer</h2><!-- end field 7d80a1fa-d725-4b72-a765-130660c4893f -->","summary":"Covers the referral of people with a suspected haematological cancer.","htmlStringContent":"<!-- begin item e4963883-b31e-440a-805e-b1a0a2b7c355 --><!-- begin field 28500783-977b-4363-ae93-acd900acf7b4 --><p>From birth onwards.</p><!-- end field 28500783-977b-4363-ae93-acd900acf7b4 --><!-- end item e4963883-b31e-440a-805e-b1a0a2b7c355 -->","topic":{"id":"7a666688-628e-59c5-9e49-275e6df96c89","topicId":"efd78d5c-f39b-47aa-a99a-712fcd440511","topicName":"Haematological cancers - recognition and referral","slug":"haematological-cancers-recognition-referral","lastRevised":"Last revised in February 2021","chapters":[{"id":"1b99cc60-959f-5937-a54d-248dd557eb06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f3b3ad5d-37b7-5a29-8e71-51338dfd53d0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"77a57871-2fdc-584c-9148-924a40f28c72","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1b4978ef-a636-510a-b98b-df2c1d638607","slug":"changes","fullItemName":"Changes"},{"id":"31156ad7-e1ac-50f7-a238-d5ab91d07500","slug":"update","fullItemName":"Update"}]},{"id":"dfef533d-7728-5775-8f82-3e745c90c505","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"388024d8-7d15-587b-8988-d7c628863b80","slug":"goals","fullItemName":"Goals"},{"id":"c513e6cc-f297-57a6-adef-8b1e4f1f8f2c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"7e3cb3e7-e51c-5962-8394-f4e0a6813935","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"3aaac357-49bc-50e7-9bc7-f68a75f8f23b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f422ee8f-401a-55f0-af2e-ec46fece5aba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7a906314-79dc-5a14-86d9-f6c963dbfaf0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0205c796-921c-5df9-aa6e-52892106204f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0075cdde-2c8e-5e7d-9734-e640651b657b","slug":"presentation","fullItemName":"Presentation"},{"id":"76cd470e-5904-5537-8ec0-73d5a2425747","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0fbae03d-8109-54c7-ad40-6ad26a3ae1b4","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"f824311f-b5dd-585e-bda3-3f418f0cd768","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"399985ab-242f-53f8-8852-45b946548d09","slug":"symptoms-suggestive-of-haematological-cancers","fullItemName":"Symptoms suggestive of haematological cancers"},{"id":"129bfa10-e11b-5bf8-aeac-2ec5de9171d7","slug":"investigations-in-primary-care","fullItemName":"Investigations in primary care"}]},{"id":"e4e9d509-0950-59c5-9f10-397475616fe8","fullItemName":"Management","slug":"management","subChapters":[{"id":"cfe47d3f-300b-5be4-b4da-3dd966fef722","slug":"referral-for-haematological-cancer","fullItemName":"Scenario: Referral for haematological cancer"}]},{"id":"61fcee5d-ff66-5a4c-91e7-4f497dfcc559","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ae7d0bdc-fc33-577f-9cfe-009a08676afa","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f9e3a44b-54f7-5761-b0f1-43617129d77e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"13a9be84-5d20-5ab3-8ea3-6490e30776d4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e1c7b25a-a475-5f05-a2da-9d859d501051","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f9ed371b-e3f7-510a-a3f5-e7c55990b468","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ff05ddf2-8028-5120-8912-94378fd8dc5a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7896863-2653-51f8-8deb-f8525add21d6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e4e9d509-0950-59c5-9f10-397475616fe8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"512aeee4-1efc-5eee-9c2f-60fda4436458","slug":"referral-timelines","fullItemName":"Referral timelines","depth":3,"htmlHeader":"<!-- begin field f345df57-257c-477d-a343-bf0ad22f517c --><h3>Referral timelines</h3><!-- end field f345df57-257c-477d-a343-bf0ad22f517c -->","summary":null,"htmlStringContent":"<!-- begin item 9cc95841-a32c-419b-9bed-424c31f7b9ee --><!-- begin field 85868c98-7a3a-4af2-82d0-8cba8ea38302 --><ul><li>The terms used in the National Institute of Health and Care Excellence (NICE) guideline <em>Suspected cancer: recognition and referral</em> are as follows:<br><ul><li>Immediate: an acute admission or referral occurring within a few hours, or even more quickly if necessary.</li><li>Urgent: to happen/be performed within 2 weeks.</li><li>Very urgent: to happen within 48 hours.</li><li>Non-urgent: the timescale generally used for a referral or investigation that is not considered very urgent or urgent.</li><li>Suspected cancer pathway referral: the patient is seen within the national target for cancer referrals (2 weeks at the time of publication of the 2015 NICE guideline <em>Suspected cancer: recognition and referral</em>).</li></ul></li></ul><!-- end field 85868c98-7a3a-4af2-82d0-8cba8ea38302 --><!-- end item 9cc95841-a32c-419b-9bed-424c31f7b9ee -->","subChapters":[{"id":"596528d2-9186-5072-8a93-7de1c454672d","slug":"basis-for-recommendation-dde","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0d2b6cdc-6597-43a2-b669-3a2521f46cfd --><h4>Basis for recommendation</h4><!-- end field 0d2b6cdc-6597-43a2-b669-3a2521f46cfd -->","summary":null,"htmlStringContent":"<!-- begin item dded5f1d-7cee-444f-9835-996bf1ccd767 --><!-- begin field 67e86891-54dc-4c1a-b476-40e8eeed7e21 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field 67e86891-54dc-4c1a-b476-40e8eeed7e21 --><!-- end item dded5f1d-7cee-444f-9835-996bf1ccd767 -->","subChapters":[]}]},{"id":"aadca272-3d73-5497-a369-b4e9f5def231","slug":"refer-an-adult-for-suspected-leukaemia","fullItemName":"Refer an adult for suspected leukaemia","depth":3,"htmlHeader":"<!-- begin field 901d9518-35fa-4174-a845-8d4a5423d647 --><h3>When should I refer an adult with suspected leukaemia?</h3><!-- end field 901d9518-35fa-4174-a845-8d4a5423d647 -->","summary":null,"htmlStringContent":"<!-- begin item 31de9a3e-e891-4ed9-8f9b-0265860431fe --><!-- begin field 1804242a-6359-453a-b3f4-d418f02eef79 --><ul><li><strong>Consider a very urgent full blood count </strong>(within 48 hours) to assess for leukaemia in adults with any of the following:<ul><li>Pallor.</li><li>Persistent fatigue.</li><li>Unexplained fever.</li><li>Unexplained persistent or recurrent infection.</li><li>Generalized lymphadenopathy.</li><li>Unexplained bruising.</li><li>Unexplained bleeding.</li><li>Unexplained petechiae.</li><li>Hepatosplenomegaly.</li></ul></li></ul><!-- end field 1804242a-6359-453a-b3f4-d418f02eef79 --><!-- end item 31de9a3e-e891-4ed9-8f9b-0265860431fe -->","subChapters":[{"id":"80b97b55-65e9-5a15-af26-a981a550ac2e","slug":"basis-for-recommendation-4f1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 616cf374-22f0-4ff6-ba28-7da913db694b --><h4>Basis for recommendation</h4><!-- end field 616cf374-22f0-4ff6-ba28-7da913db694b -->","summary":null,"htmlStringContent":"<!-- begin item 4f1cbcdb-08fd-4092-8015-4af326fb8fce --><!-- begin field 3e4f76fe-a31e-49cd-9754-586bb10f480f --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field 3e4f76fe-a31e-49cd-9754-586bb10f480f --><!-- end item 4f1cbcdb-08fd-4092-8015-4af326fb8fce -->","subChapters":[]}]},{"id":"f4b89e27-31f9-56e1-b1a1-6a0dab7f8214","slug":"refer-a-child-or-young-person-for-suspected-leukaemia","fullItemName":"Refer a child or young person for suspected leukaemia","depth":3,"htmlHeader":"<!-- begin field f96cdbbd-e5e3-46a4-b451-0237c7262d75 --><h3>When should I refer a child or young person with suspected leukaemia?</h3><!-- end field f96cdbbd-e5e3-46a4-b451-0237c7262d75 -->","summary":null,"htmlStringContent":"<!-- begin item 19f5ee2f-0610-4cd2-b555-a3244d547920 --><!-- begin field 9709ada3-f985-4299-8cee-8ef227fea5d7 --><ul><li><strong>Refer children and young people for immediate specialist assessment </strong>for leukaemia if they have unexplained petechiae or hepatosplenomegaly (new NICE recommendation for 2015).</li><li><strong>Offer a very urgent full blood count </strong>(within 48 hours) to assess for leukaemia in children and young people with any of the following:<ul><li>Pallor.</li><li>Persistent fatigue.</li><li>Unexplained fever.</li><li>Unexplained persistent infection.</li><li>Generalized lymphadenopathy.</li><li>Persistent or unexplained bone pain.</li><li>Unexplained bruising.</li><li>Unexplained bleeding.</li></ul></li></ul><!-- end field 9709ada3-f985-4299-8cee-8ef227fea5d7 --><!-- end item 19f5ee2f-0610-4cd2-b555-a3244d547920 -->","subChapters":[{"id":"bfcd0311-beae-557c-b580-fadf1df7f8c9","slug":"basis-for-recommendation-d1d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 72009000-3429-4051-8678-6c318835a5b4 --><h4>Basis for recommendation</h4><!-- end field 72009000-3429-4051-8678-6c318835a5b4 -->","summary":null,"htmlStringContent":"<!-- begin item d1d42af3-da95-4b8c-a3f8-24bffe45c184 --><!-- begin field 355118f8-cbc6-4c15-b282-293cbc237202 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field 355118f8-cbc6-4c15-b282-293cbc237202 --><!-- end item d1d42af3-da95-4b8c-a3f8-24bffe45c184 -->","subChapters":[]}]},{"id":"b5566bc9-f4a5-5239-959e-26ac8f2f6b3e","slug":"refer-an-adult-for-suspected-myeloma","fullItemName":"Refer an adult for suspected myeloma","depth":3,"htmlHeader":"<!-- begin field cc6d54e9-ff28-4403-b985-8740c777c46a --><h3>When should I refer an adult with suspected myeloma?</h3><!-- end field cc6d54e9-ff28-4403-b985-8740c777c46a -->","summary":null,"htmlStringContent":"<!-- begin item f06e4754-c5b0-40c3-81f9-73e942288909 --><!-- begin field 0e270964-74cf-494e-a884-91667a7750ce --><ul><li><strong>Offer a full blood count, blood tests for calcium and plasma viscosity or erythrocyte sedimentation rate </strong>to assess for myeloma in people aged 60 years and over with persistent bone pain, particularly back pain, or unexplained fracture.</li><li><strong>Offer very urgent protein electrophoresis and a Bence-Jones protein urine test </strong>(within 48 hours) to assess for myeloma in people aged 60 years and over with hypercalcaemia or leukopenia and a presentation that is consistent with possible myeloma.</li><li><strong>Consider very urgent protein electrophoresis and a Bence-Jones protein urine test </strong>(within 48 hours) to assess for myeloma if the plasma viscosity or erythrocyte sedimentation rate and presentation are consistent with possible myeloma.</li><li><strong>Refer people using a suspected cancer pathway referral </strong>(for an appointment within 2 weeks) if the results of protein electrophoresis or a Bence-Jones protein urine test suggest myeloma.</li></ul><!-- end field 0e270964-74cf-494e-a884-91667a7750ce --><!-- end item f06e4754-c5b0-40c3-81f9-73e942288909 -->","subChapters":[{"id":"d03b5766-de44-522c-8254-d9a7509babfe","slug":"basis-for-recommendation-671","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 69eea88a-463a-4e53-a0a1-5de5af8927f3 --><h4>Basis for recommendation</h4><!-- end field 69eea88a-463a-4e53-a0a1-5de5af8927f3 -->","summary":null,"htmlStringContent":"<!-- begin item 6713f522-0fec-40ed-92d7-5839896910c8 --><!-- begin field 0fab4f86-0bad-4731-9713-a49bf90b3be6 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field 0fab4f86-0bad-4731-9713-a49bf90b3be6 --><!-- end item 6713f522-0fec-40ed-92d7-5839896910c8 -->","subChapters":[]}]},{"id":"42b08d4c-c73e-54e7-b4da-7d1caa8d9ea9","slug":"refer-an-adult-for-suspected-non-hodgkins-lymphoma","fullItemName":"Refer an adult for suspected Non-Hodgkins lymphoma","depth":3,"htmlHeader":"<!-- begin field e04cb7da-8cc1-4d25-a0eb-430fb5910019 --><h3>When should I refer an adult with suspected non-Hodgkin’s lymphoma?</h3><!-- end field e04cb7da-8cc1-4d25-a0eb-430fb5910019 -->","summary":null,"htmlStringContent":"<!-- begin item d57c848f-fed2-4956-aabd-1ab47a00e8bf --><!-- begin field 21c90d3c-5b67-4bc1-a41f-36a21ea1dd95 --><ul><li><strong>Consider a suspected cancer pathway referral </strong>(for an appointment within 2 weeks) for non-Hodgkin's lymphoma in adults presenting with unexplained lymphadenopathy or splenomegaly. When considering referral, take into account any associated symptoms, particularly fever, night sweats, shortness of breath, pruritus, or weight loss.</li><li>Separate recommendations have been made for adults and for children and young people to reflect that there are different referral pathways. However, in practice young people (aged 16–24 years) may be referred using either an adult or children's pathway depending on their age and local arrangements.</li></ul><!-- end field 21c90d3c-5b67-4bc1-a41f-36a21ea1dd95 --><!-- end item d57c848f-fed2-4956-aabd-1ab47a00e8bf -->","subChapters":[{"id":"d121304d-178b-50c7-8ee8-40d868e5b416","slug":"basis-for-recommendation-826","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2399bfb3-f23c-4da1-a15f-78a4fce1738f --><h4>Basis for recommendation</h4><!-- end field 2399bfb3-f23c-4da1-a15f-78a4fce1738f -->","summary":null,"htmlStringContent":"<!-- begin item 82643afb-0d5e-46ee-ad31-eeb2596f0d7c --><!-- begin field 83336d85-a6d2-41fe-b051-26b29aacc15d --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field 83336d85-a6d2-41fe-b051-26b29aacc15d --><!-- end item 82643afb-0d5e-46ee-ad31-eeb2596f0d7c -->","subChapters":[]}]},{"id":"011d67ec-32be-515a-9575-0e90863752d4","slug":"refer-a-child-or-young-person-for-suspected-non-hodgkins-lymphoma","fullItemName":"Refer a child or young person for suspected Non-Hodgkins lymphoma","depth":3,"htmlHeader":"<!-- begin field 55f28177-b485-4e10-88dd-6b81b506f6b9 --><h3>When should I refer a child or young person with suspected non-Hodgkin’s lymphoma?</h3><!-- end field 55f28177-b485-4e10-88dd-6b81b506f6b9 -->","summary":null,"htmlStringContent":"<!-- begin item 63cfaf6d-e982-4094-8764-6e20122214e8 --><!-- begin field cdb41609-542e-4c9e-b460-52733cfe3aec --><ul><li><strong>Consider a very urgent referral </strong>(for an appointment within 48 hours) for specialist assessment for non-Hodgkin's lymphoma in children and young people presenting with unexplained lymphadenopathy or splenomegaly. When considering referral, take into account any associated symptoms, particularly fever, night sweats, shortness of breath, pruritus, or weight loss (new NICE recommendation for 2015).</li><li>Separate recommendations have been made for adults and for children and young people to reflect that there are different referral pathways. However, in practice young people (aged 16–24 years) may be referred using either an adult or children's pathway depending on their age and local arrangements.</li></ul><!-- end field cdb41609-542e-4c9e-b460-52733cfe3aec --><!-- end item 63cfaf6d-e982-4094-8764-6e20122214e8 -->","subChapters":[{"id":"dbe423e7-e1de-5a44-bd1d-6f1f0a235541","slug":"basis-for-recommendation-da9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b15fada8-3431-4946-b628-eb6136031226 --><h4>Basis for recommendation</h4><!-- end field b15fada8-3431-4946-b628-eb6136031226 -->","summary":null,"htmlStringContent":"<!-- begin item da92c77e-1363-4ca3-ac37-504d989ad7f5 --><!-- begin field c54bd048-63e7-421d-bd4d-3d5ecf9a1cc9 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field c54bd048-63e7-421d-bd4d-3d5ecf9a1cc9 --><!-- end item da92c77e-1363-4ca3-ac37-504d989ad7f5 -->","subChapters":[]}]},{"id":"ccf81159-1354-52cf-97d2-c25699b01d65","slug":"refer-an-adult-for-suspected-hodgkins-lymphoma","fullItemName":"Refer an adult for suspected Hodgkins lymphoma","depth":3,"htmlHeader":"<!-- begin field f4f30fda-65ab-4693-b7d0-83400ebb65f6 --><h3>When should I refer an adult with suspected Hodgkin’s lymphoma?</h3><!-- end field f4f30fda-65ab-4693-b7d0-83400ebb65f6 -->","summary":null,"htmlStringContent":"<!-- begin item dba9466f-88f5-440e-a26a-81588c430aa9 --><!-- begin field 05f038ba-f509-43d5-b0f0-cc33c445a53f --><ul><li><strong>Consider a suspected cancer pathway referral </strong>(for an appointment within 2 weeks) for Hodgkin's lymphoma in adults presenting with unexplained lymphadenopathy. When considering referral, take into account any associated symptoms, particularly fever, night sweats, shortness of breath, pruritus, weight loss, or alcohol-induced lymph node pain.</li><li>Separate recommendations have been made for adults and for children and young people to reflect that there are different referral pathways. However, in practice young people (aged 16–24 years) may be referred using either an adult or children's pathway depending on their age and local arrangements.</li></ul><!-- end field 05f038ba-f509-43d5-b0f0-cc33c445a53f --><!-- end item dba9466f-88f5-440e-a26a-81588c430aa9 -->","subChapters":[{"id":"44ec22d1-70c0-5085-8854-25f2b1988811","slug":"basis-for-recommendation-c46","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fd420c33-6bac-4cf3-a983-6fd3c1317cef --><h4>Basis for recommendation</h4><!-- end field fd420c33-6bac-4cf3-a983-6fd3c1317cef -->","summary":null,"htmlStringContent":"<!-- begin item c46a71a0-07df-45cf-b1e1-d9528a7357e4 --><!-- begin field c63c7bb7-be28-415e-8d6f-480d9b5bd5d9 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field c63c7bb7-be28-415e-8d6f-480d9b5bd5d9 --><!-- end item c46a71a0-07df-45cf-b1e1-d9528a7357e4 -->","subChapters":[]}]},{"id":"f54f7145-5b50-5301-a469-dde6dd50355d","slug":"refer-a-child-or-young-person-for-suspected-hodgkins-lymphoma","fullItemName":"Refer a child or young person for suspected Hodgkin's lymphoma","depth":3,"htmlHeader":"<!-- begin field f701a97e-5cf8-4b90-b4ab-e23792993bf5 --><h3>When should I refer a child or young person with suspected Hodgkin's lymphoma?</h3><!-- end field f701a97e-5cf8-4b90-b4ab-e23792993bf5 -->","summary":null,"htmlStringContent":"<!-- begin item 1f59e6bb-413e-4642-a2a5-371e1d4aca84 --><!-- begin field 16e05b24-f5dc-4e99-ad84-13fe16f71f58 --><ul><li><strong>Consider a very urgent referral </strong>(for an appointment within 48 hours) for specialist assessment for Hodgkin's lymphoma in children and young people presenting with unexplained lymphadenopathy. When considering referral, take into account any associated symptoms, particularly fever, night sweats, shortness of breath, pruritus, or weight loss.</li><li>Separate recommendations have been made for adults and for children and young people to reflect that there are different referral pathways. However, in practice young people (aged 16–24 years) may be referred using either an adult or children's pathway depending on their age and local arrangements.</li></ul><!-- end field 16e05b24-f5dc-4e99-ad84-13fe16f71f58 --><!-- end item 1f59e6bb-413e-4642-a2a5-371e1d4aca84 -->","subChapters":[{"id":"ff5c9f95-4aa4-51f4-a149-0792cd62a602","slug":"basis-for-recommendation-f12","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 93caa45c-9d00-43d3-a611-b13ce648b64c --><h4>Basis for recommendation</h4><!-- end field 93caa45c-9d00-43d3-a611-b13ce648b64c -->","summary":null,"htmlStringContent":"<!-- begin item f12071d3-cb5b-4e83-9b8d-cf340474b5e7 --><!-- begin field f8ae7e3b-53df-46f2-8d9b-dea08a4ef2a0 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field f8ae7e3b-53df-46f2-8d9b-dea08a4ef2a0 --><!-- end item f12071d3-cb5b-4e83-9b8d-cf340474b5e7 -->","subChapters":[]}]},{"id":"1b0970a5-d161-58d3-9f0c-ff2b9f5c5ab3","slug":"diagnostic-referral-process","fullItemName":"Diagnostic and referral process","depth":3,"htmlHeader":"<!-- begin field c2ae890b-6e21-437d-9cea-d848e8ba5256 --><h3>Diagnostic and referral process</h3><!-- end field c2ae890b-6e21-437d-9cea-d848e8ba5256 -->","summary":null,"htmlStringContent":"<!-- begin item bba25113-e2e9-4aee-9b0b-5d9c6c57e373 --><!-- begin field 47ebd72c-21bd-49ed-8fd4-f7b749eaf391 --><ul><li>Discussion with a specialist (for example, by telephone or email) should be considered if there is uncertainty about the interpretation of symptoms and signs, and whether a referral is needed. This may also enable the primary healthcare professional to communicate their concerns and a sense of urgency to secondary healthcare professionals when symptoms are not classical.</li><li>Put in place local arrangements to ensure that letters about non-urgent referrals are assessed by the specialist, so that the person can be seen more urgently if necessary.</li><li>Put in place local arrangements to ensure that there is a maximum waiting period for non-urgent referrals, in accordance with national targets and local arrangements.</li><li>Ensure local arrangements are in place to identify people who miss their appointments so that they can be followed up.</li><li>Include all appropriate information in referral correspondence, including whether the referral is urgent or non-urgent.</li><li>Use local referral proformas if these are in use.</li><li>Once the decision to refer has been made, make sure that the referral is made within 1 working day.</li><li>Take part in continuing education, peer review, and other activities to improve and maintain clinical consulting, reasoning, and diagnostic skills, in order to identify at an early stage people who may have cancer, and to communicate the possibility of cancer to the person.</li></ul><!-- end field 47ebd72c-21bd-49ed-8fd4-f7b749eaf391 --><!-- end item bba25113-e2e9-4aee-9b0b-5d9c6c57e373 -->","subChapters":[{"id":"e0d2ae28-a56d-5f99-b764-359bc4687369","slug":"basis-for-recommendation-ecf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d88c3aa2-0e42-42ea-b57e-2f87bb324fab --><h4>Basis for recommendation</h4><!-- end field d88c3aa2-0e42-42ea-b57e-2f87bb324fab -->","summary":null,"htmlStringContent":"<!-- begin item ecfe7fdd-14e4-4779-935d-df8cb4316f41 --><!-- begin field c1b51558-d279-466e-b0da-2f04eddf7613 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field c1b51558-d279-466e-b0da-2f04eddf7613 --><!-- end item ecfe7fdd-14e4-4779-935d-df8cb4316f41 -->","subChapters":[]}]},{"id":"b111c2df-edc3-54a3-b838-32edf6fef5c7","slug":"patient-information-support","fullItemName":"Patient information and support","depth":3,"htmlHeader":"<!-- begin field a38bcf22-9c54-4914-a6ec-35f9567ce076 --><h3>What patient information and support should I offer?</h3><!-- end field a38bcf22-9c54-4914-a6ec-35f9567ce076 -->","summary":null,"htmlStringContent":"<!-- begin item 1c8a1f1c-4779-4ae8-9091-0c3fd31327d1 --><!-- begin field 8410f26b-cc06-40ff-9766-c0b7a9af890f --><ul><li>Discuss with people with suspected cancer (and their carers as appropriate, taking account of the need for confidentiality) their preferences for being involved in decision-making about referral options and further investigations including their potential risks and benefits.</li><li>Explain to people who are being referred with suspected cancer that they are being referred to a cancer service. Reassure them, as appropriate, that most people referred will not have a diagnosis of cancer, and discuss alternative diagnoses with them.</li><li>Give the person information on the possible diagnosis (both benign and malignant) in accordance with their wishes for information.</li><li>The information given to people with suspected cancer and their families and/or carers should cover, among other issues:<ul><li>Where the person is being referred to.</li><li>How long they will have to wait for the appointment.</li><li>How to obtain further information about the type of cancer suspected or help before the specialist appointment.</li><li>What to expect from the service the person will be attending.</li><li>What type of tests may be carried out, and what will happen during diagnostic procedures.</li><li>How long it will take to get a diagnosis or test results.</li><li>Whether they can take someone with them to the appointment.</li><li>Who to contact if they do not receive confirmation of an appointment.</li><li>Other sources of support.</li></ul></li><li>Provide information that is appropriate for the person in terms of language, ability, and culture, recognizing the potential for different cultural meanings associated with the possibility of cancer.</li><li>Have information available in a variety of formats on both local and national sources of information and support for people who are being referred with suspected cancer.</li><li>When referring a person with suspected cancer to a specialist service, assess their need for continuing support while waiting for their referral appointment. This should include inviting the person to contact their healthcare professional again if they have more concerns or questions before they see a specialist.</li><li>If the person has additional support needs because of their personal circumstances, inform the specialist (with the person's agreement).</li><li>When cancer is suspected in a child, discuss the referral decision and information to be given to the child with the parents or carers (and the child if appropriate).</li></ul><!-- end field 8410f26b-cc06-40ff-9766-c0b7a9af890f --><!-- end item 1c8a1f1c-4779-4ae8-9091-0c3fd31327d1 -->","subChapters":[{"id":"150cf106-132b-5568-b295-c798cbf004e1","slug":"basis-for-recommendation-3b1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 84c060fe-175f-46cf-9afa-f1c7fed7cc83 --><h4>Basis for recommendation</h4><!-- end field 84c060fe-175f-46cf-9afa-f1c7fed7cc83 -->","summary":null,"htmlStringContent":"<!-- begin item 3b10906d-52e1-4e54-8e52-724bac9f3f87 --><!-- begin field 489ade26-85c4-4cd3-ae5b-01ea0580ec0d --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field 489ade26-85c4-4cd3-ae5b-01ea0580ec0d --><!-- end item 3b10906d-52e1-4e54-8e52-724bac9f3f87 -->","subChapters":[]}]},{"id":"30a9f9f5-41a2-5832-97a7-e8f010d79659","slug":"safety-netting","fullItemName":"Safety netting","depth":3,"htmlHeader":"<!-- begin field b9de7ef2-1333-4fd0-b635-ac05d2b935c3 --><h3>Safety netting</h3><!-- end field b9de7ef2-1333-4fd0-b635-ac05d2b935c3 -->","summary":null,"htmlStringContent":"<!-- begin item 7093c67e-4cdd-4d65-af88-575542cfb73a --><!-- begin field 84cf61b1-929b-4cb6-bb29-f4b9960c1035 --><ul><li>Safety netting involves active monitoring of low risk people presenting with symptoms in primary care.</li><li>Explain to people who are being offered safety netting which symptoms to look out for and when they should return for re-evaluation. It may be appropriate to provide written information.</li><li>Reassure people in the safety netting group who are concerned that they may have cancer that with their current symptoms their risk of having cancer is low.</li><li>Ensure that the results of investigations are reviewed and acted upon appropriately, with the healthcare professional who ordered the investigation taking or explicitly passing on responsibility for this. Be aware of the possibility of false-negative results for chest X-rays and tests for occult blood in faeces.</li><li>Consider a review for people with any symptom that is associated with an increased risk of cancer, but who do not meet the criteria for referral or other investigative action. The review may be planned within a time frame agreed with the person or patient-initiated if new symptoms develop, the person continues to be concerned, or their symptoms recur, persist, or worsen.</li></ul><!-- end field 84cf61b1-929b-4cb6-bb29-f4b9960c1035 --><!-- end item 7093c67e-4cdd-4d65-af88-575542cfb73a -->","subChapters":[{"id":"35849847-d0b7-5d5a-980e-eb20c3bbc5dd","slug":"basis-for-recommendation-9b9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 88dd0958-b492-42f6-b5f4-f1089374ae99 --><h4>Basis for recommendation</h4><!-- end field 88dd0958-b492-42f6-b5f4-f1089374ae99 -->","summary":null,"htmlStringContent":"<!-- begin item 9b9bb960-f135-4323-bdc5-535bc0ffcc69 --><!-- begin field 772a4e23-3530-40ef-b508-06b7cb189be2 --><p>This is a direct implementation of the National Institute for Health and Care Excellence guideline <em>Suspected cancer: recognition and r</em><em>eferral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/haematological-cancers-recognition-referral/references/\">NICE, 2015</a>].</p><!-- end field 772a4e23-3530-40ef-b508-06b7cb189be2 --><!-- end item 9b9bb960-f135-4323-bdc5-535bc0ffcc69 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}